ArticleFrontiers in neurology2025
Integrative multi-omics analysis identifies TGFA as a novel glioma susceptibility gene and therapeutic target.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between genetically determined telomere length and childhood glioma risk.Acta neuropathologica communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are among the most aggressive brain tumors, with high mortality and limited treatments. Despite genetic advances, their molecular mechanisms remain unclear, hindering diagnostic biomarkers and targeted therapies. This study investigates novel glioma susceptibility genes using integrative multi-omics. Methods: Cross-tissue transcriptome-wide association analyses integrated glioma GWAS data with eQTLs from 49 GTEx v8 tissues, utilizing UTMOST (cross-tissue), FUSION (single-tissue), and MAGMA (gene-level). Prioritized genes underwent Mendelian randomization, Bayesian colocalization, and phenome-wide association. TGFA expression was assessed in glioma samples via public genomic repositories and immunohistochemistry. Drug repurposing employed Comparative Toxicogenomics Database (CTD) and CB-Dock2 for molecular docking. Results: Five candidate genes were identified (SLC16A8, TGFA, PLA2G6, MAFF, TMEM184B), with Transforming Growth Factor Alpha (TGFA) as the strongest candidate. TGFA showed significant glioma associations across brain tissues and causal relationships via Mendelian randomization (OR: 1.27-1.39), supported by Bayesian colocalization. Elevated TGFA expression occurred in WHO grade 2/3 gliomas and 1p/19q co-deleted tumors, validated by immunohistochemistry. Drug repurposing identified 40 FDA-approved TGFA-targeting drugs; irinotecan exhibited the highest binding affinity (-62.0 kcal/mol) in docking studies. Discussion: TGFA is a novel glioma susceptibility gene with subtype-specific expression. Its therapeutic targeting offers opportunities for precision therapy, potentially advancing glioma clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.